Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors

Blood

Volumn 110, Issue 4, 2007, Pages 1301-1307

  De Falco, Giulia ^a,b   Leucci, Eleonora ^a   Lenze, Dido ^c   Piccaluga, Pier Paolo ^d   Claudio, Pier Paolo ^b   Onnis, Anna ^a   Cerino, Giovanna ^a   Nyagol, Joshua ^a,e   Mwanda, Walter ^e   Bellan, Cristiana ^a   Hummel, Michael ^c   Pileri, Stefano ^d   Tosi, Piero ^a   Stein, Harald ^c   Giordano, Antonio ^a,b   Leoncini, Lorenzo ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b TEMPLE UNIVERSITY   (United States)

^c HUMBOLDT UNIVERSITY   (Germany)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P130;

ADOLESCENT; ARTICLE; BURKITT LYMPHOMA; CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GROWTH REGULATION; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; RAJI CELL;

EID: 34548031172     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-12-064865     Document Type: Article

References (37)

1. Bellan C, Lazzi S, De Falco G, Nyongo A, Giordano A, Leoncini L. Burkitt's lymphoma: new insights into molecular pathogenesis. J Clin Pathol. 2003;56:188-192.
2. Jaffe ES, Harris NL, Stein H, Vardimar JW, eds. World Health Organization Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
3. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: MarvelouslY Complex. Adv Cancer Res. 2002;84:81-154.
4. Bellan C, De Falco G, Lazzi S, Leoncini L. Pathologic aspects of AIDS malignancies. Oncogene. 2003;22:6639-6645.
5. Lindström MS, Wiman KG. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol. 2002;12:381-387.
6. Doucet JP, Hussain A, Al-Rasheed M, et al. Differences in the expression of apoptotic proteins in Burkitt's lymphoma cell lines: potential models for screening apoptosis-inducing agents. Leuk Lymphoma. 2004;45:357-362.
7. Martinez-Delgado B, Melendez B, et al. Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas. Int J Cancer. 2002;102:15-19.
8. Sinclair AJ, Frost V. Loss of functional pRB is not a ubiquitous feature of B-cell malignancies. Br J Cancer. 1999;80:670-675.
9. Stiegler P, Giordano A. Big brothers are watching: the retinoblastoma family and growth control. Prog Mol Subcell Biol. 1998;20:25-42.
10. Claudio PP, Howard CM, Baldi A, et al. p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res. 1994;54:5556-5560.
11. Cinti C, Leoncini L, Nyongo A, et al. Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes. Am J Pathol. 2000;156:751-760.
12. Cinti C, Claudio PP, Howard CM, et al. Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2/p130 in human tumor cell lines and primary tumors. Cancer Res. 2000;60:383-389.
13. Lazzi S, Bellan C, De Falco G, et al. Expression of RB2/p130 tumor-suppressor gene in AIDS-related non-Hodgkin's lymphomas: implications for disease pathogenesis. Hum Pathol. 2002;33:723-731.
14. Nishikura K, Erikson J, Ar-Rushdi A, et al. The translocated c-myc oncogene of raji Burkitt lymphoma cells is not expressed in human lymphoblastoid cells. Proc Natl Acad Sci U S A. 1985;82:2900-2904.
15. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest. 2007;117:823-834.
16. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625-1638.
17. Hartigan JA. Clustering. Annu Rev Biophys Bioeng. 1973;2:81-101.
18. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863-14868.
19. Califano A, Stolovitzky G, Tu Y. Analysis of gene expression microarrays for phenotype classification. Proc Int Conf Intell Syst Mol Biol. 2000;8:75-85.
20. Califano A. SPLASH: structural pattern localization analysis by sequential histograms. Bioinformatics. 2000;16:341-57.
21. Jensen LJ, Gupta R, Staerfeldt HH, Brunak S. Prediction of human protein function according to gene ontology categories. Bioinformatics. 2003;19:635-642.
22. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol. 2003;4:R70.
23. Roberts JM. Evolving ideas about cyclins. Cell. 1999;98:129-132.
24. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501-1512.
25. Yasmeen A, Berdel WE, Serve H, Muller-Tidow C. E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2003;3:617-633.
26. Zini N, Trimarchi C, Claudio PP, et al. pRb2/p130 and p107 control cell growth by multiple strategies and in association with different compartments within the nucleus. J Cell Physiol. 2001;189:34-44.
27. Iwai K, Hirata K, Ishida T, et al. An anti-proliferative gene BTG1 regulates angiogenesis in vitro. Biochem Biophys Res Commun. 2004;316:628-635.
28. Koff A, Giordano A, Desai D, et al. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science. 1992;257:1689-1694.
29. Dulic V, Lees E, Reed SI. Association of human cyclin E with a periodic G1-S phase protein kinase. Science. 1992;257:1958-1961.
30. Pines J, Hunter T. Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B. Nature. 1990;346:760-763.
31. Moratz C, Kang VH, Druey KM, et al. Regulator of G protein signaling 1 (RGS1) markedly impairs Gi alpha signaling responses of B lymphocytes. J Immunol. 2000;164:1829-1838.
32. Bellan C, Lazzi S, Hummel M, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood. 2005;106:1031-1036.
33. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354:2431-2442.
34. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419-2430.
35. Leoncini L, Bellan C, Cossu A, et al. Retinoblastoma-related p107 and pRb2/p130 proteins in malignant lymphomas: distinct mechanisms of cell growth control. Clin Cancer Res. 1999;5:4065-4072.
36. Van den Bosh CA. Is endemic Burkitt's lymphoma an alliance between three infections and a tumour promoter? Lancet Oncol. 2004;5:738-746.
37. Spina D, Leoncini L, Megha T, et al. Cellular kinetic and phenotypic heterogeneity in and among Burkitt's and Burkitt-like lymphomas. J Pathol. 1997;182:145-150.